Sandro Ripa
Impact in
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
-
- Antibiotic Use and Resistance
Papers in
- Pharmacology 18
- Antibiotics Pharmacokinetics and Efficacy 18
-
- Antimicrobial Resistance in Staphylococcus 13
- Antifungal resistance and susceptibility 3
- Clostridium difficile and Clostridium perfringens research 2
- Co-authors
- Manuela Prenna (32 shared papers)Luca Agostino Vitali (14 shared papers)Pietro Emanuele Varaldo (10 shared papers)Claudia Zampaloni (8 shared papers)Dezemona Petrelli (8 shared papers)Luigi Ferrante (10 shared papers)Fiorenzo Mignini (9 shared papers)Gloria Magi (3 shared papers)
In The Last Decade
Sandro Ripa
53 papers receiving 780 citations
Peers
Comparison fields: 5 of 66
- Molecular Medicine 158
- Applied Microbiology and Biotechnology 46
- Infectious Diseases 245
- Pharmacology 109
- Endocrinology 25
Countries citing papers authored by Sandro Ripa
This map shows the geographic impact of Sandro Ripa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandro Ripa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandro Ripa more than expected).
Fields of papers citing papers by Sandro Ripa
This network shows the impact of papers produced by Sandro Ripa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandro Ripa. The network helps show where Sandro Ripa may publish in the future.
Co-authors
The 25 scholars most cited alongside Sandro Ripa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 56 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1999 | 72 | |
| 2 | 2012 | 59 | |
| 3 | 2006 | 48 | |
| 4 | 2001 | 42 | |
| 5 | 2008 | 41 | |
| 6 | 1984 | 39 | |
| 7 | 2008 | 39 | |
| 8 | In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. | 1987 | 36 |
| 9 | 2012 | 36 | |
| 10 | 2003 | 30 | |
| 11 | Purpuromycin: an antibiotic inhibiting tRNA aminoacylation. | 1997 | 29 |
| 12 | 2012 | 29 | |
| 13 | 1982 | 26 | |
| 14 | 2004 | 26 | |
| 15 | 2009 | 21 | |
| 16 | 2010 | 17 | |
| 17 | 1993 | 16 | |
| 18 | 1997 | 15 | |
| 19 | 1998 | 15 | |
| 20 | 1988 | 14 |
About Sandro Ripa
Sandro Ripa is a scholar working on Pharmacology, Infectious Diseases, Molecular Medicine, Public Health, Environmental and Occupational Health and Clinical Biochemistry, having authored 56 papers that have together received 841 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (18 papers), Streptococcal Infections and Treatments (13 papers), Antimicrobial Resistance in Staphylococcus (13 papers), Antibiotic Resistance in Bacteria (9 papers), Antifungal resistance and susceptibility (3 papers), Bacterial Identification and Susceptibility Testing (2 papers), Pneumonia and Respiratory Infections (2 papers) and Clostridium difficile and Clostridium perfringens research (2 papers). The work is most often cited by research in Molecular Medicine (158 citations), Applied Microbiology and Biotechnology (46 citations), Infectious Diseases (245 citations), Pharmacology (109 citations) and Endocrinology (25 citations). Sandro Ripa has collaborated with scholars based in Italy and Poland. Frequent co-authors include Manuela Prenna, Luca Agostino Vitali, Pietro Emanuele Varaldo, Claudia Zampaloni, Dezemona Petrelli, Luigi Ferrante, Fiorenzo Mignini, Gloria Magi, Bruna Facinelli and Marina Mingoia. Their work appears in journals such as Chemotherapy, Antimicrobial Agents and Chemotherapy, Journal of Clinical Microbiology, European Journal of Clinical Microbiology & Infectious Diseases and Clinical Microbiology and Infection.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.